[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628711":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":52,"collaborators":26,"id":54,"slug":26,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":26,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":26,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":77,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Biocells Medical","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MSC therapy","EXPERIMENTAL","200,000,000 cells per infusion",[13],"Drug: MSCs",{"label":15,"type":16,"description":17,"interventionNames":18},"Saline Solution","PLACEBO_COMPARATOR","0.9% saline infusion",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","MSCs","IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"OTHER","Placebo","Intravenous 0.9% saline infusion, volume- and appearance-matched",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Andrei Peskau, M.D.","CONTACT","+48660639936","info@biocellsmedical.com",[39],{"facility":40,"status":26,"city":41,"state":26,"zip":26,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"BioCells Medical","Warsaw","Poland",{"type":44,"coordinates":45},"Point",[46,47],21.01178,52.22977,{"lat":47,"lon":46},[50],{"name":51,"role":35,"phone":36,"phoneExt":26,"email":37},"Miron Danielevich, PhD",{"type":53,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100628711",false,"NCT07465198","Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Multiple System Atrophy (MSA-P or MSA-C)\n* Age range of 35 to 65 years\n\nExclusion Criteria:\n\n* Other major neurological disorders\n* Severe cardiac\u002Frenal\u002Fhepatic impairment\n* Prior stem cell therapy","ALL","35 Years","65 Years",{"count":64,"type":65},50,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo\u002Fcontrolled group.",[71,72],"MSA - Multiple System Atrophy","MSA",[72,74,75,76],"Multiple System Atrophy","MSC","Mesenchimal stem cells","NOT_YET_RECRUITING","2026-03-09",{"date":80,"type":81},"2026-03-11","ACTUAL",{"date":83,"type":65},"2026-09-01",{"date":85,"type":65},"2031-03-01",{"name":5,"class":6},1]